X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (50) 50
humans (48) 48
hematology (35) 35
female (29) 29
male (29) 29
middle aged (29) 29
oncology (27) 27
aged (26) 26
adult (23) 23
leukemia, myeloid, acute - drug therapy (18) 18
article (16) 16
cancer (16) 16
transplantation (16) 16
aged, 80 and over (13) 13
immunology (13) 13
abridged index medicus (12) 12
treatment outcome (12) 12
azacitidine - analogs & derivatives (11) 11
hematology, oncology and palliative medicine (11) 11
leukemia (10) 10
leukemia, myeloid, acute - genetics (10) 10
acute myeloid leukemia (9) 9
aml (9) 9
animals (9) 9
hemic and lymphatic diseases (9) 9
acute myelogenous leukemia (8) 8
cell line, tumor (8) 8
chemotherapy (8) 8
decitabine (8) 8
leukemia, myeloid, acute - pathology (8) 8
myelodysplastic syndromes (8) 8
young adult (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
expression (7) 7
mice (7) 7
mutation (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
bortezomib (6) 6
disease-free survival (6) 6
graft vs host disease - prevention & control (6) 6
group-b (6) 6
hematopoietic stem cell transplantation (6) 6
hematopoietic stem cells (6) 6
multiple-myeloma (6) 6
stem cells (6) 6
transplantation, homologous (6) 6
acute disease (5) 5
acute myeloid-leukemia (5) 5
antimetabolites, antineoplastic - therapeutic use (5) 5
azacitidine - therapeutic use (5) 5
bone-marrow-transplantation (5) 5
care and treatment (5) 5
cells (5) 5
dose-response relationship, drug (5) 5
graft vs host disease - etiology (5) 5
leukemia, myeloid, acute - metabolism (5) 5
medical research (5) 5
mortality (5) 5
older patients (5) 5
remission induction (5) 5
research (5) 5
transplantation conditioning - methods (5) 5
valproic acid (5) 5
5-aza-2'-deoxycytidine (4) 4
acute gvhd (4) 4
adolescent (4) 4
adult patients (4) 4
antimetabolites, antineoplastic - pharmacology (4) 4
antineoplastic agents - therapeutic use (4) 4
azacitidine - administration & dosage (4) 4
azacitidine - pharmacology (4) 4
combination (4) 4
cytarabine - administration & dosage (4) 4
dna methylation (4) 4
drug therapy (4) 4
histone deacetylase inhibitors (4) 4
kaplan-meier estimate (4) 4
leukemia, myeloid, acute - diagnosis (4) 4
leukemia, myeloid, acute - mortality (4) 4
lymphomas (4) 4
maximum tolerated dose (4) 4
mice, inbred nod (4) 4
mice, scid (4) 4
outcomes (4) 4
patient outcomes (4) 4
pharmacology & pharmacy (4) 4
phase-i (4) 4
primary myelofibrosis - therapy (4) 4
protein kinase inhibitors - administration & dosage (4) 4
recurrence (4) 4
stem-cell transplantation (4) 4
survival (4) 4
survival rate (4) 4
allogeneic transplantation (3) 3
antilymphocyte serum - therapeutic use (3) 3
antineoplastic agents - pharmacology (3) 3
apoptosis (3) 3
biochemistry, general (3) 3
biomedicine (3) 3
boronic acids - administration & dosage (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 5, pp. 454 - 464
Midostaurin, an oral multitargeted kinase inhibitor, is active in patients with a FLT3 mutation. Among patients with acute myeloid leukemia and this mutation,... 
TRIAL | INTERNAL TANDEM DUPLICATION | WILD-TYPE | MEDICINE, GENERAL & INTERNAL | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | DISTINCT | TYROSINE KINASE INHIBITOR | SORAFENIB | PHASE-I | YOUNGER | Humans | Middle Aged | Kaplan-Meier Estimate | Staurosporine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Staurosporine - analogs & derivatives | Protein Kinase Inhibitors - adverse effects | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Mutation | Daunorubicin - administration & dosage | Leukemia, Myeloid, Acute - genetics | Staurosporine - administration & dosage | Chemotherapy | Care and treatment | Myelocytic leukemia | Nonlymphoid leukemia | Research | Drug therapy | Cancer | Tyrosine | Medical research | Inhibitor drugs | Myeloid leukemia | Leukemia | Clinical trials | Oncology | Transplantation | Kinases | Patients | Cancer therapies | Survival | Cytarabine | Daunorubicin | Medical prognosis | Point mutation | Death | Remission | Acute myeloid leukemia | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 4/2010, Volume 107, Issue 16, pp. 7473 - 7478
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 10/2013, Volume 123, Issue 10, pp. 4144 - 4157
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends on the requirement for BCR-ABL1 kinase activity in CML... 
CHRONIC MYELOGENOUS LEUKEMIA | HEMATOPOIETIC-CELLS | MEDICINE, RESEARCH & EXPERIMENTAL | BLAST-CRISIS CML | MULTIPLE-SCLEROSIS | COMPLETE MOLECULAR REMISSION | BCR-ABL | IN-VIVO | PROTEIN PHOSPHATASE 2A | BETA-CATENIN | IMATINIB MESYLATE | Enzyme Activators - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Janus Kinase 2 - metabolism | Antineoplastic Agents - pharmacology | Wnt Signaling Pathway | Hematopoietic Stem Cells - drug effects | Propylene Glycols - pharmacology | Cell Survival - drug effects | Fingolimod Hydrochloride | Mice, Transgenic | beta Catenin - metabolism | Sphingosine - pharmacology | Xenograft Model Antitumor Assays | Sphingosine - analogs & derivatives | Animals | K562 Cells | Protein Phosphatase 2 - metabolism | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Hematopoietic Stem Cells - enzymology | Neoplastic Stem Cells - enzymology | Fusion Proteins, bcr-abl - metabolism | Apoptosis | Stem cells | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Chronic myeloid leukemia | Research | Drug therapy | Drug resistance | Medical research | Leukemia | Lymphomas | Grants | Kinases | Cancer therapies | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 02/2005, Volume 105, Issue 3, pp. 959 - 967
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2014, Volume 124, Issue 7, pp. 1183 - 1191
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2006, Volume 108, Issue 12, pp. 3674 - 3681
Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FILT3),... 
CYTOGENETIC RESPONSES | AML | INTERNAL TANDEM DUPLICATION | ACTIVATING MUTATION | PROGNOSIS | IMATINIB | TYROSINE KINASE INHIBITOR | ACUTE MYELOID-LEUKEMIA | IDENTIFICATION | HEMATOLOGY | LOOP MUTATIONS | Piperazines - administration & dosage | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Humans | Middle Aged | Quinazolines - pharmacokinetics | Male | Myelodysplastic Syndromes - blood | Protein Kinase Inhibitors - adverse effects | Proto-Oncogene Proteins c-kit - metabolism | Leukemia, Myeloid, Acute - complications | Dose-Response Relationship, Drug | fms-Like Tyrosine Kinase 3 - genetics | Protein Processing, Post-Translational - drug effects | Bone Marrow - metabolism | Drug-Related Side Effects and Adverse Reactions | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Quinazolines - administration & dosage | Phosphorylation - drug effects | Piperazines - pharmacokinetics | Myelodysplastic Syndromes - drug therapy | Protein Kinase Inhibitors - pharmacokinetics | Receptors, Platelet-Derived Growth Factor - antagonists & inhibitors | Administration, Oral | Leukemia, Myeloid, Acute - pathology | Leukemia, Myeloid, Acute - blood | Myelodysplastic Syndromes - complications | Piperazines - adverse effects | fms-Like Tyrosine Kinase 3 - metabolism | Protein Kinase Inhibitors - administration & dosage | Receptors, Platelet-Derived Growth Factor - metabolism | Bone Marrow - pathology | Quinazolines - adverse effects | Aged | Myelodysplastic Syndromes - genetics | Mutation | Myelodysplastic Syndromes - pathology | Leukemia, Myeloid, Acute - genetics | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2018, Volume 36, Issue 15, pp. 7048 - 7048
Conference Proceeding
ONCOLOGY NURSING FORUM, ISSN 0190-535X, 07/2017, Volume 44, Issue 4, pp. E185 - E193
Purpose/Objectives: To determine If the use of aromatherapy improves insomnia and other common symptoms in hospitalized patients with newly diagnosed acute... 
DEPRESSION | FATIGUE | NURSING | insomnia | BREAST-CANCER | symptom management | WOMEN | CANCER-PATIENTS | aromatherapy | ONCOLOGY | PSYCHOMETRIC EVALUATION | COGNITIVE-BEHAVIORAL THERAPY | NAUSEA | essential oils | INTERVENTION | SLEEP QUALITY INDEX
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 06/2007, Volume 321, Issue 3, pp. 953 - 960
In t(8;21) acute myeloid leukemia (AML), the AML1/ETO fusion protein promotes leukemogenesis by recruiting class I histone deacetylase (HDAC)-containing... 
HUMAN NEUROBLASTOMA-CELLS | APOPTOSIS | SODIUM VALPROATE | MYELOGENOUS LEUKEMIA | TOPOISOMERASE-I | PHARMACOLOGY & PHARMACY | FUSION TRANSCRIPT | INHIBITS PROLIFERATION | GROUP-B | CANCER | HISTONE DEACETYLASE | Oncogene Proteins, Fusion - metabolism | Caspase 9 - metabolism | Apoptosis - drug effects | Humans | Leukemia, Myeloid, Acute - metabolism | Caspase 3 - metabolism | Apoptosis - genetics | RNA Polymerase II - metabolism | Valproic Acid - pharmacology | Chromatin Assembly and Disassembly - drug effects | Repressor Proteins - antagonists & inhibitors | Cell Differentiation - genetics | Cell Nucleus - metabolism | Chromatin Immunoprecipitation | Amino Acid Chloromethyl Ketones - pharmacology | Protein Binding - drug effects | Repressor Proteins - metabolism | Promoter Regions, Genetic | Core Binding Factor Alpha 2 Subunit - metabolism | Leukemia, Myeloid, Acute - pathology | Gene Expression Regulation, Leukemic - drug effects | Histone Deacetylase 2 | Histone Deacetylases - metabolism | DNA - metabolism | Interleukin-3 - genetics | Histone Deacetylase 1 | RUNX1 Translocation Partner 1 Protein | Acetylation - drug effects | Poly(ADP-ribose) Polymerases - metabolism | Cell Differentiation - drug effects | Oncogene Proteins, Fusion - genetics | Cysteine Proteinase Inhibitors - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors | Histones - metabolism | Poly (ADP-Ribose) Polymerase-1 | Cell Nucleus - drug effects | Core Binding Factor Alpha 2 Subunit - genetics | Leukemia, Myeloid, Acute - genetics | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2008, Volume 14, Issue 8, pp. 2444 - 2449
Journal Article